Geneticure Develop Test To Personalize Hypertension Treatment

Geneticure Develop Test To Personalize Hypertension Treatment
High blood pressure, or hypertension, affects almost 1 billion people worldwide and is a leading cause of morbidity and mortality. Despite the availability of multiple drugs that lower blood pressure, it is difficult to predict which medications will best lower the individual patient’s high blood pressure. As a result, the process is often based on trial and error. Research indicates that each patient with hypertension may have a different genetic predisposition and underlying mechanism for high blood pressure, making it perfect for a more personalized or tailored approach to the specific needs for each patient.

The Minnesota-based startup Geneticure is determined to end the trial and error of hypertension medication and is helping healthcare providers determine the right course of treatment for patients. Based on a panel of genes that are involved in the regulation of blood pressure, they have developed a simple and non-invasive post-diagnostic test to quickly guide the individual patient’s ideal hypertension drug therapy. The test consists of a non-invasive cheek swap used to collect cells that contain DNA. The sample is registered on geneticure.com and sent to an accredited laboratory where it is extracted and analyzed using algorithms to determine how well the patient will respond to a particular drug and dose. When finished, Geneticure notify the doctor that results are available, together with a report through their website, which can be accessed from anywhere. In clinical studies, the test have shown to significantly reduce the time to achieve optimal blood pressure control and reduce the number of clinic visits for patients being treated for hypertension.

Hypertension is one of the most preventable contributors to disease and death in the world. Billions of dollars are wasted because doctors typically use the same drug and dose as a starting point for every patients, and then correct prescriptions over time based on how well patients do or react to it. This trial and error method is not only expensive, but could have serious consequences. Patients suffer through months of useless prescriptions and repeat office visits before getting their condition under control. Geneticure has developed an innovative test and decision-support software that could have significant impact on how hypertension is treated. The test help guide clinicians toward a more personalized approach to the prescription of hypertension medication. This approach eliminate the current trial and error that can go on for months in order to get their condition under control, reducing clinic visits and hospital admission, as well as associated healthcare costs. Most importantly, shortening the process of finding the most effective medications to lower blood pressure could improve health outcomes and save lives.

Geneticure was founded in 2013, and has since been a finalist of the Tekne Awards, Minnesota Cup, Minnesota Business Leaders in Healthcare Awards, as well as a Top-3 finalist in the American Heart Association’s Innovation Grant Challenge. The startup has raised over $1.3 million from undisclosed investors, and they are now studying two other conditions for possible future testing panels.